Cancer research center
Appears in 1 story · Last updated Nov 16, 2026
Petrylak is a member; involved in the trial
Men with metastatic castration-resistant prostate cancer have few options once hormone therapy stops working. A Yale-led Phase I/II trial reported that bavdegalutamide, a drug built to destroy the testosterone receptor, reduced prostate-specific antigen levels, shrank soft-tissue lesions and eased pain in some patients.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?